Enovis (NYSE:ENOV) Insider Acquires $49,946.56 in Stock

September 5, 2026 by InsiderTrades.com

Key Points

CEO Damien McDonald purchased 13,035 Enovis shares for approximately $249,620, increasing his direct stake by 5.57% to 247,077 shares.
Enovis exceeded quarterly expectations, reporting $0.90 in EPS versus the $0.85 consensus and $582.78 million in revenue, up 3.2% year over year.
Analysts remain broadly positive, with 10 Buy ratings and a consensus “Moderate Buy” rating, although several firms recently lowered their price targets; the consensus target is $40.38.

Enovis Corporation (NYSE:ENOV - Get Free Report) insider Oliver Engert purchased 2,458 shares of Enovis stock in a transaction dated Wednesday, September 2nd. The stock was acquired at an average price of $20.32 per share, for a total transaction of $49,946.56. Following the completion of the acquisition, the insider owned 56,098 shares of the company's stock, valued at approximately $1,139,911.36. This trade represents a 4.58% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Oliver Engert also recently made the following trade(s):

On Thursday, September 3rd, Oliver Engert acquired 5,140 shares of Enovis stock. The shares were acquired at an average price of $19.46 per share, with a total value of $100,024.40.
On Monday, June 15th, Oliver Engert acquired 1,000 shares of Enovis stock. The stock was acquired at an average cost of $20.92 per share, for a total transaction of $20,920.00.
On Thursday, June 11th, Oliver Engert purchased 1,200 shares of Enovis stock. The stock was bought at an average cost of $21.62 per share, for a total transaction of $25,944.00.
On Wednesday, June 10th, Oliver Engert acquired 1,000 shares of Enovis stock. The shares were bought at an average price of $23.00 per share, with a total value of $23,000.00.

Enovis Price Performance

Enovis stock opened at $18.58 on Friday. The company has a debt-to-equity ratio of 0.84, a current ratio of 1.98 and a quick ratio of 1.00. The stock has a market cap of $1.07 billion, a price-to-earnings ratio of -0.96 and a beta of 1.31. The firm has a 50-day moving average of $25.50 and a two-hundred day moving average of $24.20. Enovis Corporation has a 1 year low of $18.52 and a 1 year high of $34.28.

Enovis (NYSE:ENOV - Get Free Report) last issued its earnings results on Thursday, August 6th. The company reported $0.90 EPS for the quarter, topping analysts' consensus estimates of $0.85 by $0.05. Enovis had a negative net margin of 47.96% and a positive return on equity of 12.03%. The business had revenue of $582.78 million for the quarter, compared to analyst estimates of $581.84 million. During the same period last year, the company posted $0.79 earnings per share. The company's quarterly revenue was up 3.2% compared to the same quarter last year. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. On average, research analysts forecast that Enovis Corporation will post 3.15 earnings per share for the current year.

Analysts Set New Price Targets

Several brokerages have weighed in on ENOV. Wall Street Zen cut Enovis from a "buy" rating to a "hold" rating in a report on Saturday, August 8th. Citigroup restated a "market outperform" rating on shares of Enovis in a research note on Wednesday. Evercore set a $32.00 price objective on Enovis in a report on Monday, July 6th. Canaccord Genuity Group lowered their price objective on shares of Enovis from $50.00 to $45.00 and set a "buy" rating for the company in a research note on Monday, August 17th. Finally, UBS Group reiterated a "buy" rating and set a $51.00 target price (up from $50.00) on shares of Enovis in a report on Tuesday, July 28th. Ten research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Enovis currently has a consensus rating of "Moderate Buy" and an average target price of $40.38.

View Our Latest Analysis on ENOV

Hedge Funds Weigh In On Enovis

Several hedge funds have recently modified their holdings of the stock. Arax Advisory Partners purchased a new position in shares of Enovis in the 4th quarter valued at approximately $29,000. Allworth Financial LP acquired a new stake in Enovis in the 2nd quarter worth approximately $36,000. EverSource Wealth Advisors LLC grew its position in Enovis by 125.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company's stock worth $40,000 after purchasing an additional 707 shares during the last quarter. Public Employees Retirement System of Ohio purchased a new stake in Enovis during the 2nd quarter worth approximately $48,000. Finally, Danske Bank A S acquired a new position in Enovis during the 3rd quarter valued at approximately $64,000. Institutional investors and hedge funds own 98.45% of the company's stock.

Key Stories Impacting Enovis

Here are the key news stories impacting Enovis this week:

Positive Sentiment: CEO Damien McDonald bought 13,035 shares for approximately $249,620, increasing his stake by 5.57%. A substantial open-market purchase by the chief executive may signal confidence that the recent selloff has pushed the stock below its perceived value. SEC filing on CEO purchase
Positive Sentiment: Insider Oliver Engert purchased 5,140 shares worth approximately $100,024, raising his ownership by 9.16%. The additional insider buying provides another potential confidence signal for investors. SEC filing on insider purchase
Positive Sentiment: Zacks upgraded Enovis to Rank #2, or “Buy,” citing improving earnings prospects. Analysts’ upward earnings revisions and technically oversold conditions also suggest the possibility of a near-term trend reversal. Zacks Buy rating article
Positive Sentiment: Canaccord Genuity maintained a Buy rating on ENOV, reinforcing the view that the selloff may have created an attractive entry point. Canaccord Genuity rating article
Neutral Sentiment: A Q2 comparison with other specialty medical-device companies provides industry context, but the item does not identify a new material change to Enovis’ outlook. Q2 earnings comparison
Negative Sentiment: Wells Fargo lowered its ENOV price target to $33, while Citizens JMP reduced its target to $47. Although both targets remain above the current trading range, the cuts indicate more cautious valuation assumptions and may weigh on sentiment. Wells Fargo price-target article Citizens JMP price-target article

About Enovis

(Get Free Report)

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.